|
|
Previous Article | Table of Contents | Next Article 
Genetic basis of hypo-responsiveness of A/J mice to interleukin-3
KB Leslie, S Jalbert, P Orban, M Welham, V Duronio and JW Schrader
Biomedical Research Centre, University of British Columbia, Vancouver,
Canada.
Hematopoietic progenitor cells of the A/J strain of mice show a pronounced
defect in the ability to form colonies or proliferate in response to
interleukin-3 (IL-3). Comparison of immunoblots of A/J mast cells and of
mast cells from the C57BL/6 strain that respond normally to IL-3 showed
that, in both strains, a 125-kD band of the expected size was recognized by
an antibody against the beta chain of the IL-3 receptor, the AIC2A
molecule. However, in the C57BL/6 cells, there was an additional 110-kD
species not seen in cells of the A/J strain. Analyses using bone
marrow-derived mast cells from a panel of A/J x C57BL/6 and A/J x C57BL/6
recombinant inbred (RI) mice showed that the hypo-responsiveness to IL-3 is
governed by a single gene. However, the absence of this 110-kD species in
the A/J strain did not co-map with IL- 3 hypo-responsiveness but did indeed
map to the AIC2A genetic locus. These data show that this trait in the A/J
strain was due to a polymorphism of the AIC2A gene unrelated to IL-3
hypo-responsiveness. Typing of the RI strains for the markers D14Mit98,
D14Mitl4, and D14Mit133 mapped the locus determining hypo-responsiveness to
IL-3 to the subtelomeric region of chromosome 14, the region that also
bears the gene encoding the alpha chain of the IL-3 receptor (lL-3Ralpha).
Immunofluorescence analyses indicated that IL-3Ralpha protein was
undetectable on fresh bone marrow cells from A/J mice, although clearly
detectable on cells from the responder C57BL/6 strain. However, IL- 3Ralpha
was readily detectable at normal levels on A/J mast cells generated by
culture of A/J bone marrow cells in a combination of IL-3 and steel factor.
Moreover, IL-3Ralpha on these A/J mast cells appears to be functional in
that IL-3 stimulation of these cells results in tyrosine phosphorylation
events characteristic of IL-3 signaling, including tyrosine phosphorylation
of the beta chain of the IL-3 receptor, Jak-2 kinase, and SHPTP2.
Collectively, these data indicate that the hypo-responsiveness of A/J mice
to IL-3 is due to a defect in the gene encoding IL-3Ralpha and that,
although this defect gives rise to reduced expression of alpha chain on
primary bone marrow cells, this defect is not absolute and that, under
certain circumstances, A/J cells can express functional receptors.
Volume 87,
Issue 8,
pp. 3186-3194,
04/15/1996
Copyright © 1996 by The American Society of Hematology

CiteULike Connotea Del.icio.us Digg Reddit Technorati What's this?
This article has been cited by other articles:

|
 |

|
 |
 
J. Lennartsson, R. Shivakrupa, and D. Linnekin
Synergistic Growth of Stem Cell Factor and Granulocyte Macrophage Colony-stimulating Factor Involves Kinase-dependent and -independent Contributions from c-Kit
J. Biol. Chem.,
October 22, 2004;
279(43):
44544 - 44553.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M. E. Stearns, M. Wang, Y. Hu, and F.U. Garcia
Interleukin-10 Activation of the Interleukin-10E1 Pathway and Tissue Inhibitor of Metalloproteinase-1 Expression Is Enhanced by Proteasome Inhibitors in Primary Prostate Tumor Lines
Mol. Cancer Res.,
July 1, 2003;
1(9):
631 - 642.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
P. C. Orban, M. K. Levings, and J. W. Schrader
Heterodimerization of the alpha and beta Chains of the Interleukin-3 (IL-3) Receptor Is Necessary and Sufficient for IL-3-Induced Mitogenesis
Blood,
September 1, 1999;
94(5):
1614 - 1622.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
B. A. Callus and B. Mathey-Prevot
Interleukin-3-Induced Activation of the JAK/STAT Pathway Is Prolonged by Proteasome Inhibitors
Blood,
May 1, 1998;
91(9):
3182 - 3192.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
T. Papayannopoulou, G. V. Priestley, and B. Nakamoto
Anti-VLA4/VCAM-1---Induced Mobilization Requires Cooperative Signaling Through the kit/mkit Ligand Pathway
Blood,
April 1, 1998;
91(7):
2231 - 2239.
[Abstract]
[Full Text]
[PDF]
|
 |
|
|
|